Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research or investigator INDs are non-commercial INDs filed by researchers to study an unapproved drug or to study an approved drug for a new indication or in a new patient population. Emergency Use INDs, also called compassionate use or single-patient INDs, are filed for emergency use of an unapproved drug when the clinical situation does not allow sufficient time to submit an IND in accordance with 21 CFR §§ 312.23, 312.24. These are most commonly used for life-threatening conditions for which there is no standard treatment. Treatment INDs are filed to make a drug available for the treatment of serious or immediately life-threatening conditions prior to FDA approval. Serious diseases or conditions are stroke, schizophrenia, rheumatoid arthritis, osteoarthritis, chronic depression, seizures, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), and narcolepsy. Screening INDs are filed for multiple, closely related compounds in order to screen for the preferred compounds or formulations. The preferred compound can then be developed under a separate IND. Used for screening different salts, esters and other drug derivatives that are chemically different, but pharmacodynamically similar.
AAs = FFLLSSSSYY**CC*WLLLLPPPPHHQQRRRRIIIMTTTTNNKKSSRRVVVVAAAADDEEGGGG Starts = ---M---------------M---------------M---------------------------- Base1 = TTTTTTTTTTTTTTTTCCCCCCCCCCCCCCCCAAAAAAAAAAAAAAAAGGGGGGGGGGGGGGGG Base2 = TTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGG Base3 = TCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG
=== Guest appearances === Snobs (13 January 2000) – 1 episode Loose Women (16 September 2011, 1 March 2012, 26 April 2013, 3 October 2013, 24 February 2014, 4 February 2016, 4 March 2016, 3 March 2017, 6 April 2017, 7 September 2017, 2 March 2018, 27 June 2018, 11 February 2019, 20 February 2019, 19 March 2019, 6 August 2020) – 16 episodes I'm a Celebrity...Get Me Out of Here! NOW! (23–25 November 2011, 16 November 2015) – 4 episodes Peter Andre: My Life (14 December 2011) – 1 episode That Sunday Night Show (8 January 2012) – 1 episode Celebrity Juice (15 March 2012, 9 May 2013, 11 April 2019, 24 October 2019, 12 November 2020) – 5 episodes This Morning (30 March 2012, 2 April 2012, 4 April 2012, 31 August 2012, 19 September 2012, 18 January 2013, 5 April 2013, 19 April 2013, 24 April 2013, 28 November 2014, 3 December 2014, 4 December 2014, 13 May 2015, 5 February 2016, 4 July 2016, 2 August 2016, 30 April 2018, 1 October 2018, 7 January 2019, 23 January 2019, 4 February 2019, 11 February 2019, 14 August 2019, 18 December 2019, 28 June 2024) – 25 episodes The Big Quiz (15 April 2012) – 1 episode 8 Out of 10 Cats (15 June 2012, 25 January 2013, 28 January 2020) – 3 episodes Big Brother's Bit on the Side (4 July 2012, 28 July 2013, 13 May 2015, 16 June 2017) – 4 episodes Let's Do Lunch with Gino & Mel (29 August 2012) – 1 episode Celebrity Big Brother's Bit on the Side (6 September 2012, 9 January 2013, 1 September 2013, 19 August 2014, 29 January 2015, 2 February 2016, 4–5 February 2016, 1 August 2017) – 9 episodes Fake Reaction (3 January 2013) – 1 episode 8 Out of 10 Cats Does Deal or No Deal (4 January 2013) – 1 episode Food Glorious Food (24 April 2013) – 1 episode Sunday Side Up (29 December 2013) – 1 episode Who's Doing the Dishes? (3 October 2014) – 1 episode Phillip's Live 24-Hour TV Marathon (1 December 2014) – 1 episode Mel & Sue (14 January 2015) – 1 episode If Katie Hopkins Ruled the World (6 August 2015) – 1 episode Kendra on Top (21 August 2015) – 1 episode Keep It in the Family (22 August 2015) – 1 episode Safeword (27 August 2015) – 1 episode Tina Malone: My New Body (1 October 2015) – 1 episode Tricked (27 October 2015) – 1 episode The Wright Stuff (4 February 2016) – 1 episode Virtually Famous (8 March 2016) – 1 episode In Therapy (5 July 2016) – 1 episode It's Not Me, It's You (29 July 2016) – 1 episode Sky News (25 October 2016, 6 September 2024) – 2 episodes Alan Carr's Specstacular (31 December 2016) – 1 episode Through the Keyhole (4 February 2017) – 1 episode BBC Radio 1 Teen Awards (22 October 2017, 21 October 2018) Celebrity 100% Hotter (25 January 2018) – 1 episode The Generation Game (1 April 2018) – 1 episode Livin' with Lucy (10 September 2018) – 1 episode ReFreshers Week Presented By Strongbow (1 October 2018) – 1 episode Your Face or Mine? (3 October 2018) – 1 episode Good Morning Britain (30 October 2018, 19 December 2018, 4 February 2019, 1 April 2019, 24 June 2019, 7 August 2019, 13 November 2019, 25 November 2019, 8 December 2020) – 9 episodes I'll Get This (4 December 2018) – 1 episode Lorraine (4 January 2019, 18 January 2019, 23 January 2019, 8 March 2019, 9 September 2019, 30 September 2019, 15 November 2019, 11 December 2023) – 8 episodes The Jonathan Ross Show (9 March 2019) – 1 episode The Real Housewives of Cheshire (22 April 2019, 11 November 2019) – 2 episodes The Crystal Maze (21 June 2019) – 1 episode Celebrity Catchphrase (31 August 2019) – 1 episode MTV Cribs UK (16 September 2019, 7 December 2020) – 2 episodes Dancing on Ice at Christmas (22 December 2019) – 1 episode The Big Narstie Show (7 February 2020) – 1 episode Inside Missguided: Made in Manchester (12 August 2020) – 1 episode Rolling In It (15 August 2020) – 1 episode Shopping with Keith Lemon (25 October 2020) – 1 episode Celebrity Supply Teacher (17 November 2020) – 1 episode The Wheel (19 December 2020, 18 December 2021) – 2 episodes Dancing on Ice (24 January 2021) – 1 episode Piers Morgan's Life Stories (11 February 2021) – 1 episode RuPaul's Drag Race UK (18 February 2021) – 1 episode Mel Giedroyc: Unforgivable (23 February 2021) – 1 episode Sophie Ellis-Bextor's Kitchen Disco Danceathon (16 November 2021) – 1 episode Angela Scanlon's Ask Me Anything (27 November 2021) – 1 episode The Weakest Link (23 December 2021) – 1 episode Celebrity MasterChef: Christmas Cook-Off (23 December 2021) – 1 episode The Travel Show (4 February 2022) – 1 episode Springwatch (8 June 2022) – 1 episode The Big Breakfast (20 August 2022, 27 August 2022, 3 September 2022) – 3 episodes The Great Scott TreadMills Challenge (16 November 2022) – 1 episode The Greatest Snowman (26 December 2022) – 1 episode Mwy Na Daffs a Taffs (2 March 2023) – 1 episode Would I Lie to You? (24 March 2023) – 1 episode The Great Stand Up to Cancer Bake Off (26 March 2023) – 1 episode Late Night Lycett (14 April 2023) – 1 episode Steph's Packed Lunch (16 May 2023) – 1 episode The Comedy Roast for SU2C (3 November 2023) – 1 episode Celebrity Antiques Road Trip (28 November 2023) – 1 episode Blankety Blank (23 December 2023) – 1 episode The Underdog: Josh Must Win (3 April 2024) – 1 episode Drama Queens (1 May 2024) – 1 episode Who Do You Think You Are? (26 September 2024) – 1 episode Katy Perry: Night of a Lifetime (21 December 2024) – 1 episode Pointless Celebrities (25 January 2025) – 1 episode ITV Racing: Cheltenham Festival Live (13 March 2025, 12 March 2026) – 2 episodes I'm a Celebrity: Unpacked (17 April 2026, 20 April 2026) – 2 episodes
Sources: en.wikipedia.org
The Clip Editor; for recording, editing, and arranging shots. They hold the user's recorded gameplay and virtual assets. It also allows the user to place and arrange sound files and video filters. The Motion Editor; for motion adjustments over time such as blending two animations. Users can also use motion presets to select paths and manipulate different scene objects, play clips at different times, and puppeteer the characters in different positions and frames. The Graph Editor; for editing motion by creating keyframes that can be used for pose-to-pose animation. Users can either create new projects or import data from Source-based games to extend their SFM animations. SFM also supports several cinematographic effects and techniques such as motion blur, Tyndall effects, dynamic lighting, and depth of field. Users can also use inverse kinematics to manually animate movements. More advanced users can use Source's official modding tools to create environments, import new models and characters, change textures, and make scripts that make their workflow easier.
== Pharmacokinetics == Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.
The Saviz served in this capacity until it was damaged in an Israeli limpet mine attack in April 2021, when it was replaced by the MV Behshad. The Behshad, like the Saviz, is based on a cargo ship. Meanwhile, in Yemen, the Houthis, presumably with the assistance of Iranian engineers, converted a number of 10-meter-long patrol craft donated by the UAE to the Yemeni Coast Guard in the early 2010s into WBIEDs (water born improvised explosive devices). In 2017, one of these was used to attack the Saudi frigate Al Madinah. In the years since, three more WBIED designs have been built: the Tawfan-1, Tawfan-2, and Tawfan-3. 15 different types of naval mines were also produced. These are being increasingly deployed in the Red Sea, but have yet to be successful against naval vessels. The delivery of 120 km-ranged Noor and 200 km-ranged Qader AShMs, 300 km-ranged Khalij Fars ASBMs, and Fajr-4CL and "Al-Bahr Al-Ahmar" anti-ship rockets by Iran, which were unveiled during a 2022 Houthi parade, was arguably the most significant escalation in support. They combine long range, low cost, and high mobility with various types of guidance to create a weapon well-suited to the Houthi Navy. Though the Houthis' ASBM arsenal has yet to be tested, the Houthi Navy has had notable success with AShMs. On 1 October 2016, it was able to hit the UAE Navy's HSV-2 Swift hybrid catamaran with a single C-801/C-802 AShM fired from a shore battery. Although the ship managed to stay afloat, the damage was so severe that it had to be decommissioned.
=== Thermal intervention === There are two types of common thermal intervention for nipple pain, one is a warm compress while another is a cold compress. A warm compress such as a hot tea bag compress can be applied to the breast before breastfeeding to unblock the blocked milk ducts. By common practice, the solid lump that blocks the milk ducts should be resolved after 48 to 72 hours. Otherwise, assessing other possible causes of nipple pain such as lactating adenoma or malignancy is needed. It can also be applied to breast fissure sites as the vasodilation caused by the rise in temperature allows more oxygen and nutrients to help relieve pain and boost wound healing. Applying a cold compress can resolve breast engorgement. A cold gel pack, for example, can slightly reduce nipple pain caused by breast engorgement despite the effect has not yet been proved.
Sources: en.wikipedia.org
Because the Senate could not muster 60 votes per filibuster rules, funding for non-essential services ended October 1, 2025. Throughout October and into November, Senate had 14 votes, all of which failed to reach the 60-vote threshold. The shutdown ended on November 12. In early October, Senate majority leader John Thune said, "We have a majority of senators — 55 senators have already voted for this clean, short-term, nonpartisan CR," referring to a continuing resolution. Minority Leader Chuck Schumer spoke from the floor of the Senate and said 70% of Americans supported keeping the same money for the Affordable Care Act, informally "Obamacare". In addition, Schumer claimed that a survey by KFF showed that 57% of MAGA supporters also favored keeping the same money for Obamacare. The governments of 25 states sued the Trump administration regarding SNAP benefits ("food stamps") which were expected to run out on the first day of November. 1 out of 8 Americans rely on these benefits. SNAP stands for "Supplemental Nutrition Assistance Program". The administration says that they are prohibited by law from using the "contingency fund" for normal, operational expenses because this money is purposed for extraordinary events such as Hurricane Melissa. The states suing say this both goes against the wording of the law and is a "dramatic change", pointing out that the contingency fund was used for SNAP benefits during the 2019 shutdown.
=== Philanthropy and social responsibility === Since 2010, GlaxoSmithKline has several times ranked first among pharmaceutical companies on the Global Access to Medicines Index, which is funded by the Bill and Melinda Gates Foundation. In 2014, the Human Rights Campaign, an LGBT-rights advocacy group gave GSK a score of 100 per cent in its Corporate Equality Index. GSK has been active, with the World Health Organization (WHO), in the Global Alliance to Eliminate Lymphatic Filariasis (GAELF). Around 120 million people globally are believed to be infected with lymphatic filariasis. In 2012, the company endorsed the London Declaration on Neglected Tropical Diseases; it agreed to donate 400 million albendazole tablets to the WHO each year to fight soil-transmitted helminthiasis and to provide 600 million albendazole tablets every year for lymphatic filariasis until the disease is eradicated. As of 2014, over 5 billion treatments had been delivered, and 18 of 73 countries in which the disease is considered endemic had progressed to the surveillance stage. In 2009, the company said it would cut drug prices by 25 per cent in 50 of the poorest nations, release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development, and invest 20 per cent of profits from the least-developed countries in medical infrastructure for those countries.
A natural derivative of bottromycin, bottromycin D, has also been identified. It is produced in a marine Streptomyces species, strain WMMB272. Although the methyl ester is still present in bottromycin D, one of the macrocyclic valines is mutated to an alanine. The minimum inhibitory concentration (MIC) for bottromycin D was determined and found to be only slightly less active than bottromycin A2 (2 μg/mL for bottromycin D vs. 1 μg/mL for bottromycin A2). The authors postulated that greater conformational flexibility of bottromycin D may be responsible for its lower activity. No further antibacterial studies of synthetic or biosynthetic bottromycin derivatives have been reported in the literature as of 2013. The search for efficacious analogs will be enabled by bottromycin’s status as a ribosomal peptide. Analogs may be explored biosynthetically by changing the sequence of the precursor peptide; a change in amino acid sequence will lead directly to a modified bottromycin structure.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.